{"id":"https://genegraph.clinicalgenome.org/r/6659fbfc-ec99-42ce-846e-6b23ee3fc66fv1.2","type":"EvidenceStrengthAssertion","dc:description":"The X-linked *TMLHE* gene encodes trimethyllysine dioxygenase, the first enzyme in the carnitine biosynthesis pathway. Celestino-Soper et al. (2011, PMID: 21865298) identified a deletion of exon 2 of *TMLHE* resulting in enzyme deficiency in a male with autism spectrum disorder (ASD). Subsequently, Celestino-Soper et al. (2012, PMID: 22566635) reported a total of 16 male ASD probands, 6 affected male siblings, and 24 healthy adult males with deletions of exon 2, indicating that this is a relatively common variant. The frequency of TMLHE deficiency in probands from simplex autism families (9 in 2,904 or 1 in 323) was not increased compared to control males (24 in 8,787 or 1 in 366). In agreement with these findings, *TMLHE* is not constrained for truncating variants (pLI = 0 in gnomAD v2.1.1). Therefore, these deletions were not scored. Three sequence variants resulting in TMLHE deficiency (nonsense, frameshift, and missense) have been reported in males with ASD (PMID: 23092983, 25943046). These variants were also not scored given the lack of evidence regarding their implication in ASD. \n\nNo experimental evidence was applicable to the relationship between *TMLHE* and autism. Reduced Tmlhe expression caused diminished neural stem cell pools in the mouse embryonic neocortex and carnitine supplementation rescued this phenotype (PMID: 26832401). In the absence of human genetic evidence linking *TMLHE* to autism, this experimental evidence was not scored. In summary, the genetic evidence reported thus far does not provide convincing evidence to support a role for *TMLHE* in ASD, so this gene-disease relationship was classified as disputed. This classification was approved by the ClinGen Intellectual Disability/Autism GCEP on the meeting date March 2, 2021 (SOP Version 8).","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/6659fbfc-ec99-42ce-846e-6b23ee3fc66f","GCISnapshot":"https://genegraph.clinicalgenome.org/r/7a780ea6-ad4e-417a-a596-27188e327aad","calculatedEvidenceStrength":"NoKnownDiseaseRelationship","changes":[{"id":"cg:summaryChange"},{"id":"cg:classificationChange"},{"id":"cg:newEvidence"},{"id":"cg:otherTextChange"}],"contributions":[{"id":"https://genegraph.clinicalgenome.org/r/7a780ea6-ad4e-417a-a596-27188e327aad_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10006","date":"2022-09-30T20:17:45.422Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/7a780ea6-ad4e-417a-a596-27188e327aad_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10006","date":"2021-03-02T05:00:00.000Z","role":"Approver"}],"curationReasonDescription":"The authors identified a total of 16 male autism probands, 6 affected male sibs of probands, and 24 healthy adult males with deletions of exon 2, indicating that this is a relatively common variant.  TMLHE deficiency is common in control males (24 in 8,787 or 1 in 366) and was not significantly increased in frequency in probands from simplex autism families (9 in 2,904 or 1 in 323) (PMID: 22566635).","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7a780ea6-ad4e-417a-a596-27188e327aad_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ded868c5-9cfb-49bb-a45b-33ab7921df00","type":"EvidenceLine","dc:description":"In a subsequent publication, authors identified a total of 16 male autism probands, 6 affected male sibs of probands, and 24 healthy adult males with deletions of exon 2, indicating that this is a relatively common variant (Celestino-Soper et al., 2012, PMID: 22566635). TMLHE deficiency is common in control males (24 in 8,787 or 1 in 366) and was not significantly increased in frequency in probands from simplex autism families (9 in 2,904 or 1 in 323).","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ded868c5-9cfb-49bb-a45b-33ab7921df00_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21865298","allele":{"id":"https://genegraph.clinicalgenome.org/r/162ccaeb-a05c-4d91-bda7-8ddcfa8604b5","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000023.11:g.(155524633_155545096)_(155545276_155612791)del","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/31938"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Hemizygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/671c42fd-c31a-4e74-9694-37f8b1c5fdb1","type":"EvidenceLine","dc:description":"Given the functional study by Xie et al (PMID: 26832401), where the authors showed that this variant results in a catalytically dead protein, unable to rescue the neural stem cell pool depletion induced by Tmlhe deficiency in the mouse neocortex, the score could have potentially been upgraded. However, the paper by Celestino-Soper 2012 showed that deletions disrupting enzyme function are not associated with ASD, and are also present in healthy controls.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/671c42fd-c31a-4e74-9694-37f8b1c5fdb1_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23092983","allele":{"id":"https://genegraph.clinicalgenome.org/r/96239fa1-221f-4a4e-aee6-67106ae51ace","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018196.4(TMLHE):c.730G>C (p.Asp244His)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA358894"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Hemizygous"}},{"id":"https://genegraph.clinicalgenome.org/r/671c42fd-c31a-4e74-9694-37f8b1c5fdb1_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Xie et al demonstrated this variant results in a catalytically dead protein, unable to rescue the NSC  pool depletion induced by Tmlhe deficiency in the mouse neocortex.","functionalDataSupport":"No"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/7a780ea6-ad4e-417a-a596-27188e327aad_cc_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1eb045a5-a5fc-44ce-85cf-9774ac83a52a","type":"EvidenceLine","dc:description":"This paper provides contradictory evidence.","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1eb045a5-a5fc-44ce-85cf-9774ac83a52a_cc_evidence_item","type":"Finding","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22566635","rdfs:label":"Celestino-Soper et al., 2012","caseCohort":{"id":"https://genegraph.clinicalgenome.org/r/596b9925-f6f3-4d55-a044-c05f9b25bf6c","type":"Cohort","allGenotypedSequenced":3856,"alleleFrequency":0.004149377593360996,"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1eb045a5-a5fc-44ce-85cf-9774ac83a52a_cc_evidence_item"}],"numWithVariant":16,"relatedCondition":{"id":"obo:MONDO_0005258"}},"controlCohort":{"id":"https://genegraph.clinicalgenome.org/r/93bc5f8f-dd04-4448-92ac-51ad019d7a49","type":"Cohort","allGenotypedSequenced":8787,"alleleFrequency":0.002731307613519973,"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1eb045a5-a5fc-44ce-85cf-9774ac83a52a_cc_evidence_item"}],"numWithVariant":24},"method":{"id":"cg:SingleVariantAnalysis"},"statisticalSignificanceType":""}],"specifiedBy":"GeneValidityCaseControlSingleVariantAnalysisCriteria","strengthScore":0}],"specifiedBy":"GeneValidityOverallCaseControlEvidenceCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/22185330-f983-4c5d-a10c-66a350ed7fa3","type":"EvidenceLine","dc:description":"The variant was observed more than once in gnomAD v2.1.1 (3 hemizygotes).","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/22185330-f983-4c5d-a10c-66a350ed7fa3_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23092983","allele":{"id":"https://genegraph.clinicalgenome.org/r/4f1ecea0-7e7a-45d4-a096-b67ebbbd53ac","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018196.4(TMLHE):c.229C>T (p.Arg77Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA358673"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Hemizygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/4c6fd4d1-620c-43f3-83a0-0de2a627409b","type":"EvidenceLine","dc:description":"This variant was not scored because this variant had one hemizygote and one homozygote in gnomAD.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4c6fd4d1-620c-43f3-83a0-0de2a627409b_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23092983","allele":{"id":"https://genegraph.clinicalgenome.org/r/32824dae-1245-47e6-a5fc-a95e3c435ae3","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018196.4(TMLHE):c.1107G>T (p.Glu369Asp)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA358669"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Hemizygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/d08f0757-6052-4b47-92f4-012b2eb45b24","type":"EvidenceLine","dc:description":"The study by Celestino-Soper et al. (2012, PMID: 22566635) showed that although intragenic deletions in TMLHE disrupt gene function and result in enzyme deficiency and increased substrate concentration, they are also present in healthy individuals and their frequency is not increased in individuals with autism spectrum disorders. Thus, there is no evidence that truncating variants in TMLHE cause autism spectrum disorders. For this reason, this variants was not scored.","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d08f0757-6052-4b47-92f4-012b2eb45b24_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25943046","allele":{"id":"https://genegraph.clinicalgenome.org/r/d749c702-9235-477f-bc8b-d1ba8eb9a383","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018196.4(TMLHE):c.959_960AT[1] (p.Ile321fs)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA358806"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Hemizygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":0}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/7a780ea6-ad4e-417a-a596-27188e327aad_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7a780ea6-ad4e-417a-a596-27188e327aad_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1ef9f7ff-6d1b-4cd3-88a8-6cf55b1d3df5","type":"EvidenceLine","dc:description":"Because no genetic evidence was scored, no experimental evidence will be awarded points. Furthermore, this evidence is not specific to autism spectrum disorders. ","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ab95a70c-cf2f-487b-a046-178d351afccb","type":"FunctionalAlteration","dc:description":"The collective data reveal a key role for FAO (fatty acid oxidation) in controlling NSC-to-IPC transition in mammalian embryonic brain, and suggest NSC self-renewal as a cellular mechanism underlying the association between Inborn errors of metabolism (IEMs) and autism. Tmlhe directed shRNA plasmids were co-transfected with an EGFP plasmid into E12.5 murine neocortex by in utero electroporation. Embryos were returned to the uterus, allowed to further develop, and were harvested at E15.5. Quantifications based on Pax6 and Tbr2 nuclear marker labeling showed that embryonic neocortices electroporated with either of the Tmlhe shRNAs exhibited significant reductions in the fractional contribution of NSCs to total EGFP+ cell populations \nAlso, carnitine supplementation significantly enlarged the NSC pool in the Tmlhe shRNA group, it did not expand the NSC pool in the control group. \n\n","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26832401","rdfs:label":"Inborn Errors of Long-Chain Fatty Acid Î²-Oxidation"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":0}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":0}],"evidenceStrength":"Disputed","sequence":5133,"specifiedBy":"GeneValidityCriteria8","strengthScore":0,"subject":{"id":"https://genegraph.clinicalgenome.org/r/Zf-FjAaRPps","type":"GeneValidityProposition","disease":"obo:MONDO_0005258","gene":"hgnc:18308","modeOfInheritance":"obo:HP_0001417"},"version":"1.2","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_7a780ea6-ad4e-417a-a596-27188e327aad-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}